Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance

Haematologica

Volumn 94, Issue 8, 2009, Pages 1179-1181

  Kristinsson, Sigurdur Y ^a   Goldin, Lynn R ^b   Björkholm, Magnus ^a   Turesson, Ingemar ^c   Landgren, Ola ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Familial aggregation; MGUS; Solid tumors; Susceptibility

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BLADDER CANCER; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC MYELOID LEUKEMIA; COLON TUMOR; CONNECTIVE TISSUE TUMOR; CONTROLLED STUDY; ESOPHAGUS TUMOR; FEMALE; GALLBLADDER TUMOR; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; KIDNEY TUMOR; LARYNX TUMOR; LETTER; LIVER TUMOR; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MOUTH TUMOR; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVARY TUMOR; PANCREAS TUMOR; POPULATION BASED CASE CONTROL STUDY; PROSTATE TUMOR; RECTUM TUMOR; RELATIVE; RISK ASSESSMENT; SALIVARY GLAND TUMOR; SKIN TUMOR; SMALL INTESTINE TUMOR; SOLID TUMOR; SPINAL CORD CANCER; STOMACH TUMOR; TESTIS TUMOR; THYROID TUMOR; UTERUS TUMOR; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASMS; PARAPROTEINEMIAS; RISK FACTORS; YOUNG ADULT;

EID: 68049135887     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.006346     Document Type: Letter

References (12)

1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
2. Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
4. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759-64.
5. Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et al. Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden. Blood 2009; [Epub ahead of print].
6. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8.
7. Camp NJ, Werner TL, Cannon-Albright LA. Familial myeloma. N Engl J Med 2008;359:1734-5.
8. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med 2008;359:152-7.
9. Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. J Urol 2001;166:2129-33.
10. Anagnostopoulos A, Galani E, Gika D, Sotou D, Evangelopoulou A, Dimopoulos MA. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Ann Hematol 2004;83:658-60.
11. Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood 2000;95:1869-71.
12. Bourguet CC, Grufferman S, Delzell E, DeLong ER, Cohen HJ. Multiple myeloma and family history of cancer. A case-control study. Cancer 1985;56:2133-9.